Skip to main content
Top
Published in: Clinical and Experimental Medicine 8/2023

Open Access 09-08-2023 | Pruritus | Review

An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma

Authors: Man Hu, Jörg Scheffel, Daniel Elieh-Ali-Komi, Marcus Maurer, Tomasz Hawro, Martin Metz

Published in: Clinical and Experimental Medicine | Issue 8/2023

Login to get access

Abstract

Primary cutaneous T-cell lymphomas (CTCL), which include mycosis fungoides (MF) and Sézary syndrome (SS), are a group of lymphoproliferative disorders characterized by clonal accumulation of neoplastic T-lymphocytes in the skin. Severe pruritus, one of the most common and distressing symptoms in primary CTCL, can significantly impair emotional well-being, physical functioning, and interpersonal relationships, thus greatly reducing quality of life. Unfortunately, effectively managing pruritus remains challenging in CTCL patients as the underlying mechanisms are, as of yet, not fully understood. Previous studies investigating the mechanisms of itch in CTCL have identified several mediators and their corresponding antagonists used for treatment. However, a comprehensive overview of the mediators and receptors contributing to pruritus in primary CTCL is lacking in the current literature. Here, we summarize and review the mediators and receptors that may contribute to pruritus in primary CTCL to explore the mechanisms of CTCL pruritus and identify effective therapeutic targets using the PubMed and Web of Science databases. Studies were included if they described itch mediators and receptors in MF and SS. Overall, the available data suggest that proteases (mainly tryptase), and neuropeptides (particularly Substance P) may be of greatest interest. At the receptor level, cytokine receptors, MRGPRs, and TRP channels are most likely important. Future drug development efforts should concentrate on targeting these mediators and receptors for the treatment of CTCL pruritus.
Literature
14.
15.
go back to reference Lansigan F. Navigating the treatment choices for mycosis fungoides. Oncology. 2010;24:508.PubMed Lansigan F. Navigating the treatment choices for mycosis fungoides. Oncology. 2010;24:508.PubMed
29.
31.
go back to reference Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–49. https://doi.org/10.1111/bjd.19574.CrossRefPubMed Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–49. https://​doi.​org/​10.​1111/​bjd.​19574.CrossRefPubMed
43.
go back to reference Newsom M, Hrin ML, Hamid RN, et al. Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol Online J. 2021;27. Newsom M, Hrin ML, Hamid RN, et al. Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. Dermatol Online J. 2021;27.
48.
go back to reference Tran J, Morris L, Vu A, Duvic M. Development of Sézary syndrome following the administration of dupilumab. Dermatol Online J. 2020;26. Tran J, Morris L, Vu A, Duvic M. Development of Sézary syndrome following the administration of dupilumab. Dermatol Online J. 2020;26.
66.
go back to reference Fredholm S, Gjerdrum LM, Willerslev-Olsen A, et al. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res. 2014;34:5277–86.PubMed Fredholm S, Gjerdrum LM, Willerslev-Olsen A, et al. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides. Anticancer Res. 2014;34:5277–86.PubMed
89.
go back to reference Guarneri F, Minciullo PL, Mannucci C, et al. IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol. 2015;47:156–8.PubMed Guarneri F, Minciullo PL, Mannucci C, et al. IL-31 and IL-33 circulating levels in allergic contact dermatitis. Eur Ann Allergy Clin Immunol. 2015;47:156–8.PubMed
132.
go back to reference Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95:542–8. https://doi.org/10.2340/00015555-2047.CrossRefPubMed Roblin D, Yosipovitch G, Boyce B, et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol. 2015;95:542–8. https://​doi.​org/​10.​2340/​00015555-2047.CrossRefPubMed
175.
233.
242.
go back to reference Wu Z, Kong M, Chen J, et al. Continous epidural butorphanol decreases the incidence of intrathecal morphine-related pruritus after cesarean section: a randomized, double-blinded, placebo-controlled trial: epidural butorphanol decreases the incidence of intrathecal morphine-related pruritus. Cell Biochem Biophys. 2014;70:209–13. https://doi.org/10.1007/s12013-014-9884-9.CrossRefPubMed Wu Z, Kong M, Chen J, et al. Continous epidural butorphanol decreases the incidence of intrathecal morphine-related pruritus after cesarean section: a randomized, double-blinded, placebo-controlled trial: epidural butorphanol decreases the incidence of intrathecal morphine-related pruritus. Cell Biochem Biophys. 2014;70:209–13. https://​doi.​org/​10.​1007/​s12013-014-9884-9.CrossRefPubMed
249.
go back to reference Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41:533–9.PubMed Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol. 1999;41:533–9.PubMed
271.
305.
go back to reference Dummer R, Duvic M, Scarisbrick J, et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014;25:1807–12. https://doi.org/10.1093/annonc/mdu231.CrossRefPubMed Dummer R, Duvic M, Scarisbrick J, et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol. 2014;25:1807–12. https://​doi.​org/​10.​1093/​annonc/​mdu231.CrossRefPubMed
Metadata
Title
An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
Authors
Man Hu
Jörg Scheffel
Daniel Elieh-Ali-Komi
Marcus Maurer
Tomasz Hawro
Martin Metz
Publication date
09-08-2023
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 8/2023
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01141-x

Other articles of this Issue 8/2023

Clinical and Experimental Medicine 8/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.